Background: Chronic hepatitis C virus infection is a worldwide health problem that could cause complications such as cirrhosis or even hepatocellular carcinoma. Hepatitis C virus (HCV) infection has increased preponderance of diabetes mellitus (DM) type 2 and insulin resistance.
Objectives: Our goal is to determine whether the most recent direct acting antiviral (DAA) medications for the HCV treatment are linked to improvements in insulin resistance and other related glycemic parameters in type 2 DM patients. Patients and Methods: This prospective, observational study was conducted on 40 diabetic patients aged >18 years treated from HCV by DAA. Baselines HCV PCR and liver function tests were obtained before DAA. Pre-and post-treatment change of the glycemic profile including calculated homeostatic model assessment of insulin resistance (HOMA-IR) lab results were taken.
Results: Impact of DDA drugs on our subjects' glycemic profile showed improvements of all glycemic indices (Fasting plasma glucose (FPG), fasting insulin, HBA1c and HOMA-IR with p-value < 0.001.  HCV PCR changes after treatment was positivity correlated significantly especially with FPG and HOMA-IR (r value 0.501 and 0.478 respectively) with p-value < 0.05.
Conclusion: We concluded that DAAs improved insulin resistance and related glycemic control parameters after eradication of HCV. Our results suggest that HCV take a part in glucose homeostasis. Liver function before treatment could be a predictor of improvement of insulin resistance.